Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine

Chiara Tani1, Maria Stella1, Danilo Donnarumma1

  • 1Novartis Vaccines and Diagnostics, Via Fiorentina, 1 53100 Siena, Italy.

Vaccine
|January 28, 2014
PubMed

Insights

Bexsero, a new vaccine against serogroup B meningococcal disease, uses detergent extracted outer membrane vesicles (DOMVs). This study confirms the vaccine

Area of Science:

  • Vaccinology
  • Microbiology
  • Analytical Chemistry

Background:

  • Meningococcal disease poses a significant global health threat, with serogroup B being a primary concern due to the lack of a widely available vaccine.
  • Bexsero(®) is a novel vaccine approved for preventing serogroup B meningococcal infections, utilizing detergent extracted outer membrane vesicles (DOMVs) from a New Zealand epidemic strain.

Purpose of the Study:

  • To perform additional characterization of DOMVs used in Bexsero(®) beyond standard quality control.
  • To assess the robustness and accuracy of the Hi3 label-free LC-MS(E) methodology for DOMV protein content analysis.
  • To compare the consistency of DOMV protein composition across multiple production lots.

Main Methods:

  • Utilized the Hi3 label-free liquid chromatography-tandem mass spectrometry (LC-MS(E)) technique.
  • Analyzed the protein content of detergent extracted outer membrane vesicles (DOMVs).
  • Applied nonparametric hypothesis testing and complementary log-log linear regression for quantitative analysis.

Main Results:

  • Successfully validated the Hi3 LC-MS(E) methodology for DOMV characterization.
  • Quantified approximately 100 proteins per DOMV preparation, with ~90% consistently identified as outer membrane proteins.
  • Demonstrated high consistency in the quantification of 21 key proteins across six DOMV production lots, representing 85-92% of the total protein content.

Conclusions:

  • The Hi3 quantification methodology is robust for characterizing a wide range of proteins in DOMVs.
  • The manufacturing process for Bexsero(®) DOMV components exhibits high reproducibility and consistency.
  • These findings support the quality and reliability of the Bexsero(®) vaccine's active components.

Related Concept Videos